TY - JOUR
T1 - An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma
T2 - A Trial of the ECOG-ACRIN Cancer Research Group (E2204)
AU - Berlin, Jordan D.
AU - Feng, Yang
AU - Catalano, Paul
AU - Abbruzzese, James L.
AU - Philip, Philip A.
AU - McWilliams, Robert R.
AU - Lowy, Andrew M.
AU - Benson, Al B.
AU - Blackstock, A. William
N1 - Publisher Copyright:
© 2017 S. Karger AG, Basel.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objectives: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). Methods: Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab. Cycles 7-12 included cetuximab/bevacizumab with gemcitabine. Cycles were 2 weeks. Frequency of specific toxicities was summarized for each treatment arm at two times during the study, after chemotherapy but prior to chemoradiation and after all therapy. Results: A total of 127 patients were randomized (A, n = 65; B, n = 62). Prior to chemoradiation, the overall rate for toxicities of interest was 10% for arm A and 2% for arm B. After all therapy, the overall rates for toxicities of interest were 30 and 25% for arms A and B, respectively. Overall median OS and DFS were 17 and 11 months, respectively, which is not a significant improvement over expected survival rates for historical controls. Conclusions: Both treatments were tolerable with manageable toxicities, and were safe enough for a phase III trial had this been indicated.
AB - Objectives: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). Methods: Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab. Cycles 7-12 included cetuximab/bevacizumab with gemcitabine. Cycles were 2 weeks. Frequency of specific toxicities was summarized for each treatment arm at two times during the study, after chemotherapy but prior to chemoradiation and after all therapy. Results: A total of 127 patients were randomized (A, n = 65; B, n = 62). Prior to chemoradiation, the overall rate for toxicities of interest was 10% for arm A and 2% for arm B. After all therapy, the overall rates for toxicities of interest were 30 and 25% for arms A and B, respectively. Overall median OS and DFS were 17 and 11 months, respectively, which is not a significant improvement over expected survival rates for historical controls. Conclusions: Both treatments were tolerable with manageable toxicities, and were safe enough for a phase III trial had this been indicated.
KW - Bevacizumab
KW - Cetuximab
KW - Chemoradiation
KW - Randomized phase II
KW - Resected pancreatic carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85031816293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031816293&partnerID=8YFLogxK
U2 - 10.1159/000480295
DO - 10.1159/000480295
M3 - Article
C2 - 29040974
AN - SCOPUS:85031816293
SN - 0030-2414
VL - 94
SP - 39
EP - 46
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 1
ER -